In the context of viral hepatitis, pan-CypIs have proven to be of therapeutic value to treat chronic infections for hepatitis C [24,25,26], while in a transgenic mouse line carrying the HBV genome, the pan-cyclophilin inhibitor CRV431 reduced liver HBV DNA levels and moderately reduced serum HBsAg levels [31]. Here, PPIB is linked to viral hepatitis.